GIGA-564 is under clinical development by GigaGen and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GIGA-564’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GIGA-564 overview

GIGA-564 is under development for the treatment of solid tumor and melanoma. They act by targeting CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4). The drug candidate is fully human monoclonal antibody with validated cellular activity which are developed based on surge technology. It is administered through intravenous route.

GigaGen overview

GigaGen is a biotechnology company that develops advancing transformative antibody drugs to treat diseases of immune deficiencies, infectious diseases and checkpoint-resistant cancers. The company pipeline product includes GIGA-564 which treats oncology. It also discovers and develops monoclonal, polyclonal antibody therapies and T-cell receptors. GigaGen carries out single-cell antibody discovery and development platforms. The company’s novel technology platforms include polyclonal antibody therapies for the treatment of infectious diseases. It has collaborated with academic and biopharmaceutical researchers in the areas of antibody discovery, massively polyclonal, natural repertoire antibodies and cancer repertoire analysis. GigaGen is headquartered in San Francisco, California, the US.

For a complete picture of GIGA-564’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.